Edition:
United Kingdom

BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

3.59USD
17 Dec 2018
Change (% chg)

-- (--)
Prev Close
$3.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,970
52-wk High
$14.28
52-wk Low
$3.57

Latest Key Developments (Source: Significant Developments)

Bioxcel Therapeutics Announces FDA Acceptance Of IND For Lead Neuroscience Candidate, BXCL501 For Acute Treatment Of Agitation
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND FOR LEAD NEUROSCIENCE CANDIDATE, BXCL501 FOR THE ACUTE TREATMENT OF AGITATION.BIOXCEL THERAPEUTICS INC SAYS PATIENT RECRUITMENT INITIATED AND DATA READ-OUT EXPECTED IN 1H 19.BIOXCEL THERAPEUTICS INC SAYS RESULTS TO SUPPORT DOSE SELECTION FOR REGISTRATION TRIAL EXPECTED TO INITIATE IN 2019.BIOXCEL THERAPEUTICS INC SAYS WITH FDA ACCEPTANCE OF IND, CO IS ON-TRACK TO DOSE SUBJECTS BY YEAR-END, WITH DATA EXPECTED IN FIRST HALF OF 2019.  Full Article

Bioxcel Therapeutics Qtrly Loss Per Share $0.31
Friday, 9 Nov 2018 

Nov 9 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS THIRD QUARTER 2018 QUARTERLY RESULTS AND PROVIDES BUSINESS UPDATE.BIOXCEL THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.31.BIOXCEL THERAPEUTICS INC - AS OF SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS TOTALED $47.1 MILLION..BIOXCEL THERAPEUTICS INC - EXPECT THAT DATA FROM IV DEX STUDIES IN PATIENTS WITH SCHIZOPHRENIA AND SDAT WILL BE AVAILABLE BY END OF 2018.  Full Article

Bioxcel Therapeutics Expands Immuno-Oncology Partnership With Nektar
Monday, 24 Sep 2018 

Sept 24 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS EXPANDS IMMUNO-ONCOLOGY PARTNERSHIP WITH NEKTAR INTO CLINICAL DEVELOPMENT IN PANCREATIC CANCER.BIOXCEL THERAPEUTICS INC - CO AND NEKTAR ARE EXPANDING THEIR ONGOING RESEARCH COLLABORATION INTO A NEW CLINICAL PARTNERSHIP.BIOXCEL THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, CO WILL BE RESPONSIBLE FOR INITIATING AND MANAGING CLINICAL PROGRAM.  Full Article

Bioxcel Therapeutics Reports Q2 Net Loss Per Share $0.1
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.CLINICAL PROGRAMS IN NEUROSCIENCE (BXCL501) AND IMMUNO-ONCOLOGY (BXCL701) ON TRACK.QTRLY NET LOSS PER SHARE $0.1.  Full Article

Bioxcel Therapeutics Reports Positive Results From Phase 1B Trial Of Intravenously-Dosed Dexmedetomidine Supporting Bxcl501 Development
Wednesday, 27 Jun 2018 

June 27 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS POSITIVE RESULTS FROM PHASE 1B TRIAL OF INTRAVENOUSLY-DOSED DEXMEDETOMIDINE SUPPORTING BXCL501 DEVELOPMENT.BIOXCEL THERAPEUTICS INC - OPTIMAL EXPOSURE LEVELS FOR DEVELOPING BXCL501 SUBLINGUAL THIN FILM IDENTIFIED.BIOXCEL - RESULTS SUPPORT CLINICAL EVALUATION OF DEXMEDETOMIDINE IN ACUTE TREATMENT OF AGITATION RESULTING FROM NEUROPSYCHIATRIC DISORDERS & DEMENTIA.BIOXCEL THERAPEUTICS INC - IV FORMULATION OF DEX WAS WELL TOLERATED.  Full Article

Bioxcel Therapeutics Reports Q1 Loss Per Share $0.37
Monday, 14 May 2018 

May 14 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.BIOXCEL THERAPEUTICS INC QTRLY LOSS PER SHARE $0.37.  Full Article

Bioxcel Therapeutics Shares Open Slightly Above IPO Price
Thursday, 8 Mar 2018 

March 8 (Reuters) - :BIOXCEL THERAPEUTICS INC SHARES OPEN AT $11.02 IN DEBUT ON NASDAQ VERSUS IPO PRICE OF $11.00/SHARE.  Full Article